Several optic neuropathies, including glaucoma, lead to optic nerve axonal damage and retinal ganglion cell (RGC) loss via apoptosis. Glaucmatous optic neuropathy is characterized by progressive axonal damage in the optic nerve head, which progresses to RGC death and visual field deficits.

Since recognition of the promising role for silent information regulators in the longevity of Caenorhabditis elegans, many studies have focused on the cellular mechanisms underlying sirtuins. Sirtuin 1 (SIRT1) is a nicotinamide adenine dinucleotide (NAD)+-dependent histone deacetylase, which is linked to cellular stress responses and survival functions including metabolic control, DNA repair, inflammation, apoptosis, and neuroprotection. Studies conducted to date indicate that SIRT1 contributes to neuroprotection during ischemia and in the neurodegenerative diseases. SIRT1 overexpression by resveratrol pretreatment mediates delayed neuronal death following cerebral ischemic damage in rats. In contrast, inhibition of SIRT1 increases cortical...
neuronal death after oxygen-glucose deprivation.\textsuperscript{10}

Of several downstream targets of SIRT1 activation, regulation of peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) activity plays a prominent role.\textsuperscript{11-13} PGC-1α is a transcriptional co-activator linked with mitochondrial biogenesis and function.\textsuperscript{14-16} Accumulating evidence indicates that abnormal regulation of PGC-1α, which contributes to altered neuronal metabolism, occurs in neurodegenerative diseases.\textsuperscript{17,18}

Polyphenol resveratrol, a molecule containing two phenyl rings separated by a methylene bridge, was the first compound identified as a sirtuin stimulator.\textsuperscript{19} SIRT1 is present in the nucleus and cytoplasm of cells of all ocular structures, including the cornea, lens, iris, ciliary body, and retina.\textsuperscript{20} Recently, Zuo et al.\textsuperscript{21} reported that SIRT1 overexpression or resveratrol treatment delayed RGC loss and loss of pupillary light responses by reducing superoxide production, following an optic nerve crush injury. Similarly, an anti-apoptotic effect of SIRT1 on cultured RGCs was reported in an in vitro model of hypoxia.\textsuperscript{22} In parallel, considering the wide spectrum of activities in which SIRT-1 participates, modulation of SIRT1 activity may have great importance in RGC fate in glaucomatous optic neuropathy. However, the neuroprotective effects of resveratrol on RGCs have not yet been reported in eyes with chronic intraocular pressure (IOP) elevation. Previously, our group reported that injection of 0.3% carbomer solution to the anterior chamber was an effective and reproducible method of producing chronic IOP elevation and progressive RGC death, including axonal loss, in rats.\textsuperscript{23} The current study investigated the effects of resveratrol on RGC survival, including the mechanisms of action, in a rat model of chronic IOP elevation.

**Materials and Methods**

**Animal Use**

All experiments were conducted in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. The protocol was approved by the Institutional Animal Care and Use Committee of Chonnam National University Hospital. Sprague-Dawley rats, each weighing 245-255 g, were individually housed under controlled lighting conditions (12 h light/12 h dark) and were given tap water and food ad libitum throughout the duration of the study.

**Induction of IOP Elevation**

IOP elevation was induced as described previously.\textsuperscript{23} Briefly, anesthesia was induced in rats by intramuscular injection of a mixture of tiletamine/zolazepam (Zoletil 50, Virbac, Nice, France) 20 mg/kg combined with xylazine hydrochloride (Rompun, Bayer Korea, Seoul, Korea) 5 mg/kg. After tetracaine hydrochloride was topically applied, a sterile lid speculum was placed in the eye. The cornea was gently punctured near the limbus using a 31 gauge needle to decompenstate the anterior chamber as much as possible prior to injection. After this entry wound, 20 uL of 0.3% carbomer solution was injected into the anterior chamber using a 31-gauge needle. After each procedure, antibiotic ointment was applied. A topical antibiotic was applied twice each day, and eyes were observed for infection twice each day.

**IOP Measurement**

IOP was measured every day for 1 week and then weekly thereafter using a tonometer (TonoLab; Tiolat Oy, Helsinki, Finland) (Fig. 1). IOP measurements were conducted consistently at the same time in the afternoon. Rats were anaesthetized by intramuscular injection of tiletamine/zolazepam combined with xylazine hydrochloride. In order to minimize the effects of general anesthesia, IOP was measured as soon as the rat was lightly sedated and lid reflex was lost, which occurred within 1 minute. In total, 5 recordings were obtained from each eye, and the mean of these 5 recordings was calculated in order to determine IOP. Mean and peak IOP were measured at each time point. Integral IOP for each animal was defined as the area under the curve for each animal.\textsuperscript{23}

**Pharmacological Treatment**

Resveratrol (Sigma, St. Louis, MO, USA) was dissolved in 50% ethanol and diluted 10-fold in phosphate buffered
saline (PBS; pH 7.4). In order to evaluate the neuroprotective effects of resveratrol, rats were randomly divided into 2 experimental groups and injected intraperitoneally with saline (n = 65) or resveratrol (10 mg/kg/day; n = 25) daily until sacrifice.

**Tissue Preparations**
Rats were anesthetized as described above. Both eyes were enucleated, and rats were euthanized by CO₂ inhalation. The retinas were dissected from the choroid and fixed in 4% paraformaldehyde in PBS (pH 7.4) for 2 hours at 4°C for retinal flat mounting, or dehydrated in a graded series of ethanol solutions and then embedded in polyester wax. For western blot analyses, whole retinas were used immediately or frozen at -70°C until use.

**Western Blot Analyses**
Retinal tissues were homogenized in a glass-Teflon Potter homogenizer in lysis buffer (PRO-PREPTM, iNtRoN Biotechnology, Seoul, Korea). Each sample (10 µg) was separated on a 10% polyacrylamide mini gel. After protein transfer, membranes were blocked for 1 hour at room temperature in Tris-buffered saline Tween-20 solution (TBS-T; 10 mM Tris–HCl [pH 7.6], 150 mM NaCl, and 0.1% Tween-20) containing 5% non-fat dry milk. After blocking, membranes were incubated overnight at 4°C with a rabbit polyclonal anti-PGC-1α antibody (1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit polyclonal anti-SIRT1 (1:1,000; Cell Signaling Technology, Danvers, MA, USA), mouse monoclonal anti-glial fibrillary acidic protein (anti-GFAP) (1:3,000; Cell Signaling Technology), or mouse monoclonal anti-β-actin antibody (1:4,000; Santa Cruz Biotechnology) in TBS-T solution containing 5% non-fat dry milk. After 3 washes with TBS-T, the membranes were incubated for 1 hour at room temperature with peroxidase-conjugated goat anti-mouse immunoglobulin G (IgG) (1:3,000; Santa Cruz Biotechnology) or peroxidase-conjugated goat anti-rabbit IgG (1:3,000; Cell Signaling Technology) in TBS-T containing 5% nonfat dry milk. Signals were visualized by enhanced chemiluminescence and quantified using a LAS-3,000 image analyzer (Fujifilm, Tokyo, Japan).

**Retinal Whole Mounts and Brn3a Staining**
At 4 weeks after chronic IOP elevation, retinas were dis-
sected from enucleated eyes and flattened. Retinas were then immersed in PBS containing 30% sucrose for 24 hours at 4°C, then frozen for 15 minutes at -70°C, blocked in PBS containing 1% bovine serum albumin and 0.5% Triton X-100, and incubated with a polyclonal goat anti-brain-specific homeobox/POU domain protein 3a (Brn3a) antibody (1:100; Santa Cruz Biotechnology) for 72 hours at 4°C. After washing, the retinas were incubated with the secondary antibody, Alexa Fluor-568-conjugated donkey anti-goat IgG antibody (1:250; Invitrogen, Carlsbad, CA, USA) for 4 hours, and subsequently washed with PBS. To evaluate the loss of RGCs, each retinal quadrant was divided into 3 zones (center, middle, and peripheral retina) corresponding to 1/6, 3/6, and 5/6 of the retinal radius. RGCs were counted in 32 distinct areas of 0.09 mm$^2$ (2 areas in the center, 3 areas in the middle, and 3 areas at the periphery of each retinal quadrant) by 2 blinded investigators, and mean score was calculated. Images were analyzed using a fluorescence microscope (Nikon Eclipse E600; Nikon, Tokyo, Japan).

**Immunohistochemical Analyses**

Immunohistochemical staining of 7-µm wax sections of full-thickness retinas was performed by immunofluorescence with the following primary antibodies: mouse monoclonal anti-GFAP antibody (1:250; Cell Signaling Technology), mouse monoclonal anti-SIRT1 (1:100; Cell Signaling Technology), or goat polyclonal anti-Brn3a antibody (1:100; Santa Cruz Biotechnology). Tissues were blocked with 1% bovine serum albumin in PBS for 1 hour at room temperature to prevent nonspecific background staining, and were then incubated with primary antibodies overnight at 4°C. The sections were washed several times, incubated with Alexa Fluor 488-conjugated chicken anti-mouse IgG (1:250; Invitrogen) or Alexa Fluor 546-conjugated rabbit anti-goat IgG (1:250; Invitrogen) for 4 hours at 4°C, and then washed again with PBS. The sections were counterstained with Hoechst 33342/PBS (0.1 µg/mL; Invitrogen). Images were analyzed using a Zeiss LSM 510 confocal microscope (Carl Zeiss, Jena, Germany).

**Statistical Analyses**

Experiments were repeated at least 3 times. The data presented represent means ± standard deviations. Groups were compared using the unpaired Student’s $t$-test. Comparison between more than 2 conditions was performed using one-way analysis of variance and Bonferroni post-hoc multiple comparison tests. $p$-values < 0.05 were considered statistically significant.

**Results**

**IOP Elevation**

The mean IOP of control eyes and carbomer-injected eyes are described in Table 1. The mean IOP of the carbomer-in-

|                           | Mean IOP (mmHg) | $p$-value* |
|---------------------------|-----------------|------------|
|                           | Control         | IOP + S    | IOP + RV   | P1   | P2   | P3   |
| Baseline (n = 90)         | 9.60 ± 0.83     | 9.80 ± 1.21| 9.93 ± 1.03| 0.595| 0.461| 0.838|
| 1 day (n = 90)            | 9.71 ± 1.27     | 18.86 ± 3.30| 19.43 ± 3.52| < 0.001*| < 0.001*| 0.701|
| 3 days (n = 90)           | 10.46 ± 0.88    | 29.60 ± 5.70| 29.40 ± 7.16| < 0.001*| < 0.001*| 0.967|
| 5 days (n = 90)           | 10.25 ± 1.60    | 32.13 ± 5.25| 34.87 ± 4.52| < 0.001*| < 0.001*| 0.255|
| 7 days (n = 90)           | 9.80 ± 0.68     | 35.93 ± 6.94| 36.71 ± 6.12| < 0.001*| < 0.001*| 0.571|
| 2 weeks (n = 80)          | 10.33 ± 1.18    | 40.08 ± 9.05| 39.00 ± 8.89| < 0.001*| < 0.001*| 0.478|
| 3 weeks (n = 70)          | 10.73 ± 1.18    | 33.17 ± 9.24| 33.50 ± 7.66| < 0.001*| < 0.001*| 0.898|
| 4 weeks (n = 30)          | 10.13 ± 0.83    | 24.42 ± 4.08| 25.08 ± 6.43| < 0.001*| < 0.001*| 0.977|

Values are described as mean ± standard deviation. P1 Control vs IOP elevation + S, P2 Control vs IOP elevation + RV treatment, P3 IOP elevation + S vs IOP elevation + RV treatment. IOP = intraocular pressure; S = saline; RV = resveratrol.

* Mann-Whitney $U$ test for between-groups comparisons with Bonferroni correction for multiple comparisons; $^*$ $p < 0.05$. 

Journal of the Korean Glaucoma Society
Heo H, et al. : Neuroprotective effect of resveratrol

jected eyes remained significantly higher than control eyes until 4 weeks after carbomer injection, and reached a peak at 2 weeks after injection, with a mean IOP of 40.08 ± 9.05 mmHg in eyes from rats treated with saline and 39.00 ± 8.89 mmHg in eyes from rats treated with resveratrol (Table 1). The integral IOPs of the carbomer-injected eyes at 1, 2, 3, and 4 weeks after injection were significantly different from control eyes (Table 2). However, there was no significant difference in mean IOP and integral IOP in comparisons between carbomer-injected eyes from rats treated with saline and carbomer-injected eyes from the resveratrol group at any experimental time point.

Expression of SIRT1, PGC-1α, and GFAP

The expressions of SIRT1, PGC-1α, and GFAP were evaluated at 1, 2, 3, and 4 weeks after chronic IOP elevation, using western blot analyses (Fig. 1). SIRT1 and PGC-1α expression were downregulated and reached a minimum at 3 weeks compared to control retinas without chronic IOP elevation (0.65 ± 0.13-fold and 0.78 ± 0.14-fold, respectively; p < 0.05) (Fig. 2A, 2B, 2D, 2E). In contrast, GFAP expression was upregulated and reached a maximum at 3 weeks (Fig. 2C, 2F).

Table 2. Integral intraocular pressure at each follow-up period after injection of 0.3% carbomer solution

|          | Control | IOP + S | IOP + RV | P1 | P2 | P3 |
|----------|---------|---------|----------|----|----|----|
| 1 week (n = 90) | 80.38 ± 4.01 | 214.82 ± 29.78 | 223.29 ± 14.82 | < 0.001† | < 0.001† | 0.541 |
| 2 week (n = 80) | 149.50 ± 5.58 | 471.88 ± 71.00 | 487.04 ± 42.60 | < 0.001† | < 0.001† | 0.410 |
| 3 week (n = 70) | 221.83 ± 11.78 | 728.25 ± 110.46 | 740.79 ± 71.05 | < 0.001† | < 0.001† | 0.551 |
| 4 week (n = 30) | 294.46 ± 13.80 | 929.79 ± 121.88 | 945.83 ± 92.94 | < 0.001† | < 0.001† | 0.590 |

Values are described as mean ± standard deviation. P1 Control vs IOP elevation + S, P2 Control vs IOP elevation + RV treatment, P3 IOP elevation + S vs IOP elevation + RV treatment. IOP = Intraocular pressure; S = Saline; RV = Resveratrol. *Mann-Whitney U test for between-groups comparisons with Bonferroni correction for multiple comparisons; †p < 0.05.
compared to control retinas without chronic IOP elevation (1.48 ± 0.21-fold; p < 0.05) (Fig. 2C, 2F).

**Effect of Resveratrol on Expression of SIRT1, PGC-1α, and GFAP**

We evaluated whether resveratrol treatment affected the expression of SIRT1, PGC-1α, and GFAP at 3 weeks after chronic IOP elevation (Fig. 1). Resveratrol significantly prevented downregulation of SIRT1 expression compared to retinas from saline treated rats (0.66 ± 0.02-fold vs. 0.95 ± 0.05-fold; p < 0.05, n = 10 retinas/group) (Fig. 3A, 3C). A similar effect of resveratrol on PGC-1α expression was evident when compared to retinas from saline treated rats (0.87 ± 0.02-fold vs. 1.08 ± 0.02-fold; p < 0.05) (Fig. 3B, 3D).

*Figure 3.* The effect of resveratrol on SIRT1 and PGC-1α expression in retinas from rats experiencing chronic intraocular pressure (IOP) elevation. Resveratrol treatment significantly prevented the downregulation of SIRT1 and PGC-1α expression compared with retinas from saline treated rats (A, B, C, D) (n = 10 retinas/group). Relative intensity of chemiluminescence for SIRT1 and PGC-1α was normalized to β-actin. Counterstaining with Hoechst 33342 in a control retina (E, blue). Immunohistochemical staining with SIRT1 (F, green). Immunohistochemical staining with Brn3a, a marker for retinal ganglion cells (RGC; G, red). Merged image (H). These findings indicate that RGCs express SIRT1 protein (arrowheads). When the primary antibody was omitted (control for SIRT1 immunohistochemistry) there was no labeling by the secondary antibody in retinas from untreated rats (I). Compared to control retinas (J), SIRT1 immunoreactivity was decreased in retinas from rats with chronic IOP elevation (K). However, resveratrol treatment increased SIRT1 immunoreactivity in retinas from rats with chronic IOP elevation (L). SIRT1 = sirtuin 1; PGC-1α = Peroxisome proliferator-activated receptor gamma coactivator-1α; IOP = intraocular pressure; S = saline; RV = resveratrol; GCL = ganglion cell layer; IPL = inner plexiform layer; RGC = ganglion cells. *Significant at p < 0.05 between control and chronic IOP elevation + saline. **Significant at p < 0.05 between chronic IOP elevation + saline and chronic IOP elevation + resveratrol. Error bars, standard deviation. Scale bar, 20 μm.
Heo H, et al. : Neuroprotective effect of resveratrol

3D). In contrast, resveratrol significantly suppressed GFAP upregulation in comparison with retinas from saline treated rats (1.31 ± 0.08-fold vs. 1.00 ± 0.04-fold; p < 0.05) (Fig. 4A, 4B).

The ganglion cell layer (GCL) was visualized using Hoechst 33342 (Fig. 3E), SIRT1 (Fig. 3F), and Brn3a (Fig. 3G) staining. Upon double SIRT1 and Brn3a immunohistochemical staining (Fig. 3H), GCL neurons positive for SIRT1 were co-immunostained for Brn3a, an RGC marker. Indicating that RGCs express SIRT1. In the absence of the primary SIRT1 antibody, there was no secondary antibody labeling in untreated rat retinas (negative control) (Fig. 3I). SIRT1 immunoreactivity was reduced in the GCL of saline treated retinas compared to retinas from untreated rats without chronic IOP elevation (Fig. 3J, 3K). Resveratrol treatment increased SIRT1 immunoreactivity in retinas with chronic IOP elevation (Fig. 3L). Without primary GFAP antibody, there was no labeling by the secondary antibody in retinas from untreated rat (negative control) (Fig. 4C). GFAP immunoreactivity was increased in the nerve fiber layer and GCL of retinas from saline treated rats compared to control retinas (n = 5 retinas/group) (Fig. 4D, 4E). Moreover, resveratrol treatment decreased GFAP immunoreactivity in retinas (Fig. 4F).

**Figure 4.** The effect of resveratrol on GFAP expression in retinas from rats experiencing chronic intraocular pressure (IOP) elevation. Resveratrol treatment significantly suppressed the upregulation of GFAP expression compared retinas from saline treated rats (A, B; n = 10 retinas/group). Relative intensity of chemiluminescence of GFAP protein bands was normalized to β-actin. When the primary antibodies were omitted (control for GFAP immunohistochemistry), there was no secondary antibody binding (C). Compared with control retinas (D), GFAP immunoreactivity was increased in retinas from saline treated rats with chronic IOP elevation (E). However, resveratrol treatment decreased GFAP immunoreactivity in retinas from rats with chronic IOP elevation (F; n = 5 retinas/group). GFAP = glial fibrillary acidic protein; IOP = intraocular pressure; S = saline; RV = resveratrol; GCL = ganglion cell layer; IPL = inner plexiform layer; INL = inner nuclear layer; OPL = outer plexiform layer; ONL = outer nuclear layer. *Significant at p < 0.05 between control and chronic IOP elevation + saline. **Significant at p < 0.05 between chronic IOP elevation + saline and chronic IOP elevation + resveratrol. Error bars, standard deviation. Scale bars, 20 μm.

**Effect of Resveratrol on RGC Loss after Chronic IOP Elevation**

RGC survival was evaluated by immunohistochemistry of retinal whole mounts using an anti-Brn3a antibody. Signif-
Significant differences in RGC density occurred between retinas from resveratrol treated rats and those from saline treated rats at 4 weeks after chronic IOP elevation. The saline group experienced significant RGC losses of approximately 36% in the center, 39% in the middle, and 43% in the periphery, compared to the control group without chronic IOP elevation. Resveratrol treatment prevented RGC loss by approximately 48% in the center, 57% in the middle, and 54% in the periphery compared to retinas from saline treated rats ($p < 0.05$, n = 10 retinas/group) (Fig. 5, Table 3). These results suggest that resveratrol has a neuroprotective effect on RGCs in conditions of chronic IOP elevation.

**Table 3.** The effect of resveratrol on retinal ganglion cell survival in retina with chronic IOP elevation

| Cell density (cell/mm² ± SD) | Control | Control + RV | IOP + RV | IOP + RV |
|-----------------------------|---------|--------------|-----------|-----------|
| Center                      | 2,128 ± 556 | 2,191 ± 556 | 1,373 ± 394* | 2,033 ± 398† |
| Middle                      | 1,903 ± 534 | 1,995 ± 552 | 1,174 ± 418* | 1,851 ± 565† |
| Periphery                   | 1,562 ± 609 | 1,542 ± 573 | 897 ± 370*  | 1,378 ± 518† |

Values are described as mean ± standard deviation.
IOP = intraocular pressure; S = saline; RV = resveratrol.

* $p < 0.05$, comparison between control and IOP elevation + S; † $p < 0.05$, comparison between IOP elevation + S and IOP elevation + RV.

Figure 5. The effect of resveratrol on retinal ganglion cell (RGC) survival in retinas from rats experiencing chronic intraocular pressure (IOP) elevation. Retinal flat mounts are shown for control (A), control-resveratrol (B), chronic IOP elevation+saline (C), and chronic IOP elevation+resveratrol groups (D) (n = 10 retinas/group). Quantitative analysis of RGC survival (E). RGC = retinal ganglion cell; IOP = intraocular pressure; S = saline; RV = resveratrol. *Significant at $p < 0.05$ between control and chronic IOP elevation + saline. **Significant at $p < 0.05$ between chronic IOP elevation + saline and chronic IOP elevation + resveratrol. Error bars, standard deviation. Scale bars, 20 μm.
Discussion

RGC death in optic neuropathies, including glaucoma, are thought to occur via several mechanisms, such as interruption of retrograde neurotrophin transport, mitochondrial dysfunction, oxidative stress, and excitotoxicity.24-26 Under these harmful conditions, RGCs may undergo apoptosis, but they can potentially be rescued by neuroprotective agents. To date, however, there is no effective treatment to prevent RGC death in diverse optic neuropathies. Resveratrol is a natural polyphenolic compound mainly found in grape skins.27 Resveratrol significantly increases SIRT1 activity through an allosteric interaction, resulting in an increase in SIRT1 affinity for both NAD+ and the acetylated substrate.19 Moreover, SIRT1 physically interacts with and deacetylates PGC-1α at multiple lysine sites, consequently increasing PGC-1α activity.28 PGC-1α is a transcriptional co-activator implicated in mitochondrial biogenesis and respiration through the regulating several genes, such as nuclear respiratory factors and mitochondrial transcription factor A.1529,30 Emerging evidence has indicates that SIRT1 is an important anti-aging molecules and may participate in preventing several age-related ocular diseases.31-33 In addition, several neurodegenerative diseases including Huntington’s disease and Alzheimer’s disease are associated with reduced SIRT1 expression.34,35 In the retina, the neuroprotective effects of SIRT1 may be regulated by inhibiting oxidative stress-related retinal damage, apoptosis-related retinal death, and inflammation.32,36,37 Increased PGC1α expression is implicated in elevated mitochondrial biogenesis and efficient respiration, in parallel with elevated expression of mitochondrial reactive oxygen species (ROS) detoxifying enzymes.38,39 In neurons, mitochondria play important roles in the maintenance of cellular homeostasis, including adenosine triphosphate (ATP) production by oxidative phosphorylation, maintaining intracellular calcium for controlling neuronal excitability, ROS production, and regulation of death signaling pathways.40,41 Previous studies have suggested that mitochondrial dysfunction contributes to RGC death in cultured RGC-5 cells, as well as in ischemic and glaucomatous animal models.42-46 Similarly, our group previously demonstrated that ischemia reperfusion injury by acute IOP elevation increases expression of a dynamin related guanosine triphosphatase (GTPase) (dynamin-related protein 1 [Drp-1]), which plays a key role in mitochondrial fragmentation at the onset of apoptosis in ischemic mouse retinas. Furthermore, the neuroprotective dipeptide carnosine significantly decreases RGC loss by lowering Drp-1 expression in ischemic mouse retinas.47 Increased GFAP expression is commonly interpreted as a cellular marker of retinal stress and astrogliosis.48 This augmented expression suggests increased stress in retinas with chronic IOP elevation, and thus these findings can be interpreted as evidence that resveratrol treatment exerts a protective effect during harmful stress, which results in RGC survival. Moreover, resveratrol ameliorates mitochondrial dysfunction in retinas with chronic IOP elevation.

In conclusion, resveratrol treatment decreases RGC death by upregulating SIRT1 and PGC-1α expression and by downregulating GFAP expression in rat retinas with chronic IOP elevation. Resveratrol has multiple avenues by which it maintains cellular homeostasis. Therefore, we believe that the neuroprotective effect of resveratrol on RGCs is not limited to one factor, rather involves multiple mechanisms, most of which may be interrelated. The neuroprotective effects of resveratrol combined with its minimal side effects make it a promising novel neuroprotective treatment for optic neuropathies, including glaucoma. Precise delineation of resveratrol’s pharmacologic mechanisms and dosing regimens are required in order for preclinical results to develop into future treatments in clinical practice.

References

1. Levin LA. Axonal loss and neuroprotection in optic neuropathies. Can J Ophthalmol 2007;42:403-8.
2. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363:1711-20.
3. Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001;410:227-30.
4. Landry J, Sutton A, Tafrov ST, et al. The silencing protein SIR2 and its homologs are NAD-dependent protein...
deacetylases. Proc Natl Acad Sci USA. 2000;97:5807-11.
5. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007;404:1-13.
6. Hernández-Jiménez M, Hurtado O, Cuartero MI, et al. Silent information regulator 1 protects the brain against cerebral ischemic damage. Stroke 2013;44:2333-7.
7. Duan W. Targeting sirtuin-1 in Huntington’s disease: rationale and current status. CNS Drugs 2013;27:345-52.
8. Srivastava S, Haigis MC. Role of sirtuins and caloric restriction in neuroprotection: implications in Alzheimer’s and Parkinson’s diseases. Curr Pharm Des 2011;17:3418-33.
9. Della-Morte D, Dave KR, DeFazio RA, et al. Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience 2009;159:993-1002.
10. Zhu H, Wang Z, Zhu X, et al. Icariin protects against brain injury by enhancing SIRT1-dependent PGC-1alpha expression in experimental stroke. Neuropharmacology 2010;59:70-6.
11. Nemoto S, Fergusson MM, Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional co-activator PGC-1[alpha]. J Biol Chem 2005;280:16456-60.
12. Nisoli E, Carruba MO. Nitric oxide and mitochondrial biogenesis. J Cell Sci 2006;119(Pt 14):2855-62.
13. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006;127:1109-22.
14. Delerive P, Wu Y, Burris TP, et al. PGC-1 functions as a transcriptional coactivator for the retinoid X receptors. J Biol Chem. 2002;277:3913-7.
15. Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, transcriptional coactivator for the retinoid X receptors. J Cell Biol 2006;177:1725-31.
16. Zolezzi JM, Silva-Alvarez C, Ordenes D, et al. Peroxisome proliferator-activated receptor (PPAR)γ and PPARα agonists modulate mitochondrial fusion-fission dynamics: relevance to reactive oxygen species (ROS)-related neurodegenerative disorders? PLoS One 2013;8:e64019.
17. Qin W, Haroutunian V, Katsel P, et al. PGC-1 alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol 2009;66:352-61.
18. Chaturvedi RK, Calingasan NY, Yang L, et al. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington’s disease following chronic energy deprivation. Hum Mol Genet 2010;19:3190-205.
19. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003;425:191-6.
20. Jaliffa C, Amequame I, Dansault A, et al. Sirt1 involvement in rd10 mouse retinal degeneration. Invest Ophthalmol Vis Sci 2009;50:3562-72.
21. Zuo L, Khan RS, Lee V, et al. SIRT1 promotes RGC survival and delays loss of function following optic nerve crush. Invest Ophthalmol Vis Sci 2013;54:5097-102.
22. Balaiya S, Ferguson LR, Chalam KV. Evaluation of sirtuin role in neuroprotection of retinal ganglion cells in hypoxia. Invest Ophthalmol Vis Sci 2012;53:4315-22.
23. Kim HG, Park JW, Park SW. Experimental chronic ocular hypertension by anterior chamber injection of 0.3% carbomer solution in the rat. Clin Exp Ophthalmol 2013;41:404-12.
24. Berkelaar M, Clarke DB, Wang YC, et al. Axotomy results in delayed death and apoptosis of retinal ganglion cells in adult rats. J Neurosci 1994;14:4368-74.
25. Snider WD, Elliott JL, Yan Q. Axotomy-induced neuronal death during development. J Neurobiol 1992;23:1231-46.
26. Chrysostomou V, Rezania F, Trounce IA, Crowston JG. Oxidative stress and mitochondrial dysfunction in glaucoma. Curr Opin Pharmacol 2013;13:12-5.
27. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006;5:493-506.
28. Rodgers JT, Lerin C, Haas W, et al. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005;434:113-8.
29. Wu Z, Puigserver P, Andersson U, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999;98:115-24.
30. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003;24:78-90.
31. Zheng T, Lu Y. Changes in SIRT1 expression and its downstream pathways in age-related cataract in humans. Curr Eye Res 2011;36:449-55.
32. Anekonda TS, Adams G. Resveratrol prevents antibody-induced apoptotic death of retinal cells through upregulation of Sirt1 and Ku70. BMC Res Notes 2008;1:122.
33. Kubota S, Kurihara T, Ebinuma M, et al. Resveratrol prevents light-induced retinal degeneration via suppressing activator protein-1 activation. Am J Pathol 2010;177:1725-31.
34. Parker JA, Arango M, Abderrahmane S, et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 2005;37:349-50.
35. Qin W, Yang T, Ho L, et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 2006;281:21745-54.
36. Peng CH, Cherng JY, Chiou GY, et al. Delivery of Oct4 and SirT1 with cationic polyurethanes-short branch PEI to aged retinal pigment epithelium. Biomaterials 2011;32:9077-88.
37. Kubota S, Ozawa Y, Kurihara T, et al. Roles of AMP-activated protein kinase in diabetes-induced retinal inflammation. Invest Ophthalmol Vis Sci 2011;52:9142-8.
38. Finkel T. Cell biology: a clean energy programme. Nature 2006;444:151-2.
39. Austin S, Klimcakova E, St-Pierre J. Impact of PGC-1α on the topology and rate of superoxide production by the mitochondrial electron transport chain. Free Radic Biol Med 2011;51:2243-8.
40. Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. Cell 2006;125:1241-52.
41. Schon EA, Manfredi G. Neuronal degeneration and mitochondrial dysfunction. J Clin Invest 2003;111:303-12.
42. Ju WK, Kim KY, Angert M, et al. Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina. Invest Ophthalmol Vis Sci 2009;50:707-16.
43. Ju WK, Kim KY, Duong-Polk KX, et al. Increased optic atrophy type 1 expression protects retinal ganglion cells in a mouse model of glaucoma. Mol Vis 2010;16:1331-42.
44. Ju WK, Kim KY, Lindsey JD, et al. Intraocular pressure elevation induces mitochondrial fission and triggers OPA1 release in glaucomatous optic nerve. Invest Ophthalmol Vis Sci 2008;49:4903-11.
45. Ju WK, Kim KY, Lindsey JD, et al. Elevated hydrostatic pressure triggers release of OPA1 and cytochrome C, and induces apoptotic cell death in differentiated RGC-5 cells. Mol Vis 2009;15:120-34.
46. Park SW, Kim KY, Lindsey JD, et al. A selective inhibitor of drp1, mdivi-1, increases retinal ganglion cell survival in acute ischemic mouse retina. Invest Ophthalmol Vis Sci 2011;52:2837-43.
47. Ji YS, Park JW, Heo H, et al. The neuroprotective effect of carnosine (β-alanyl-L-histidine) on retinal ganglion cell following ischemia-reperfusion injury. Curr Eye Res 2014;39:634-41.
48. Woldemussie E, Wijono M, Ruiz G. Müller cell response to laser-induced increase in intraocular pressure in rats. Glia 2004;47:109-19.